SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is experiencing a notable surge amid widespread reports of potential takeover interest from multiple rivals, with community discussion focusing on the company's deeply undervalued assets and strong free cash flow as catalysts for a potential bidding war and short squeeze.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending with high conviction as Dr. PSS's recent presentation on Anktiva's potential to prevent and cure cancer sparks widespread community excitement, fueling intense short squeeze speculation and institutional interest amidst perceived regulatory resistance.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending with notable pre-earnings strength, fueled by expectations of an 18th consecutive beat and raise and the continued integration of its OpenAI partnership into its AI marketing platform. Community sentiment is divided between strong bullish conviction in its proprietary data moat and concerns over broader software sector headwinds potentially leading to a "sell the news" event.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday (WDAY) is trending after its latest earnings release, which, despite beating estimates, triggered a significant aftermarket sell-off amidst concerns about future subscription growth and mixed reactions to its AI acquisition strategy and recent leadership changes. The community is sharply divided, with bulls viewing the dip as a buying opportunity while bears contend that AI disruption fundamentally challenges the SaaS business model, anticipating further declines for the enterprise software giant.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as a key director's substantial insider purchase and a new LPGA marketing partnership signal strong long-term confidence, even while the community debates its undervalued status, the impact of increased growth-oriented expenses, and ongoing buyout speculation.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending following a significant strategic collaboration with Astellas for its VIR-5500 prostate cancer asset, bolstered by positive Phase 1 trial data and multiple analyst upgrades. The community is actively discussing the substantial financial commitment and the potential for a short squeeze, given the tight float and notable short interest.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae (FNMA) is trending as renewed speculation intensifies regarding its release from conservatorship and a potential uplisting to the NYSE. The community is actively discussing recent bullish statements from FHFA officials, anticipation surrounding former President Trump's potential actions, and the company's consistent profitability, all contributing to hopes for a significant, long-awaited valuation unlock.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as the community eagerly anticipates its Q3 earnings, with discussions focused on updated guidance and the potential impact of a recent FDA safety notice regarding specific product lots. Persistent speculation surrounds a possible short squeeze or outright acquisition, fueled by the stock's perceived undervaluation and strategic repositioning, despite ongoing frustrations with its price action.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors anticipate upcoming earnings, with community discussion centered on its strategic pivot to AI and high-performance computing data centers, substantial backing from Google, and a notable short interest. Many believe these factors position the company for a significant short squeeze and long-term growth in the burgeoning AI infrastructure sector.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited (ANPA) is trending due to its acquisition of TikTok icon Khaby Lame's core company, sparking community excitement about potential explosive growth in digital content. However, the move is also drawing significant skepticism and warnings of a pump-and-dump, with many questioning its valuation compared to fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5 Dividend ETFs Beating the S&P 500 This Year

Five dividend ETFs -- DFJ, SCHD, FDL, HDV and EYLD -- have outpaced SPY in 2026 as investors rotate toward quality income plays.

<ul class="summary-bullets"><li>Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes.</li><li>The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.</li><li>For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data.</li></ul>Pfizer Inc. (PFE) stock was in the spotlight on Tuesday after the company reported positive updates from a study testing weight loss treatment and a better-than expected fourth quarter print.However, <a href="https://stocktwits.com/symbol/PFE">PFE shares</a> were down 2% in pre-market trading on Tuesday as investors appeared to remain cautious about growth risks and the long road ahead for its GLP-1 pipeline.&nbsp;<h2 class="st-heading-2">Positive Topline Results For Weight Loss Treatment&nbsp;</h2>Pfizer reported positive topline results from its Phase 2b VESPER-3 study evaluating PF’3944, an ultra-long-acting injectable GLP-1 receptor agonist, in adults with obesity or overweight without type 2 diabetes.The trial aimed to determine whether patients could maintain weight loss while switching from weekly to once-monthly injections and whether the treatment would retain a favorable safety profile.The study met its primary endpoint, delivering statistically significant weight reduction across all tested doses. Participants achieved up to 12.3% mean placebo-adjusted weight loss at week 28. PF’3944 was generally well tolerated, with mostly mild to moderate gastrointestinal side effects and limited treatment discontinuations. The safety profile remained consistent with the broader GLP-1 drug class.“Based on the monthly dosing efficacy and tolerability demonstrated in this trial, we remain confident in our plan to include a higher 9.6 mg monthly maintenance dose of PF’3944 in Phase 3,” said Jim List, Chief Internal Medicine Officer.Following its acquisition of Metsera and a global licensing deal with YaoPharma, Pfizer said it is accelerating its obesity treatment pipeline. The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.<h2 class="st-heading-2">Q4 Earnings Snapshot</h2>Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted earnings between $2.80 and $3 per share. The company said the outlook includes roughly $5 billion in expected COVID-19 product sales and a projected $1.5 billion year-over-year revenue hit from certain products losing exclusivity.The company posted a 2% decline in FY2025 revenue at $62.6 billion with adjusted earnings of $3.22 per share.For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data. It also posted a better-than-expected EPS of $0.66.<h2 class="st-heading-2">What Did Stocktwits Users Say?</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes. PFE was among the top trending tickers on the platform.<figure class="image"><img src="https://news.stocktwits-cdn.com/PFE_jpg_91e98a5cdf.webp" alt="PFE.jpg" width="928" height="111"><figcaption>PFE's Sentiment Meter and Message Volumes in Pre-Market on Feb. 3, 2026 | Source: Stocktwits</figcaption></figure>One user expects multiple upcoming catalysts this year for the stock.<stembedurl>https://stocktwits.com/giuseppe8469/message/643776399</stembedurl>Another user highlighted key support and resistance levels.<stembedurl>https://stocktwits.com/Jas45z/message/643776263</stembedurl>The stock has gained around 1.5% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-pre-market-what-moving-average-indicates/cZbiqlvR4ln">SOFI Stock Hovers Around 200-DMA — A Make-or-Break Test Looms</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling?

Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion, while its FY2025 revenue came in at $62.6 billion.

Equity

<ul class="summary-bullets"><li>It expects full-year ongoing earnings per diluted share of approximately $7.00, which was lower than the analyst expectations of $7.21 per share.</li><li>The company said it expects debt reduction of approximately $400 million as it continues to review all options to reduce debt.</li><li>Its FY2025 sales of $15.5 billion, fell 6.5% compared to FY2024.</li></ul>Shares of Whirlpool slumped more than 8% on Thursday as weak fourth-quarter earnings and lower forecast for FY26 disappointed investors.&nbsp;The weak forecast prompted strong criticism from the retail traders on the performance of the company.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WHR trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;One bearish user on Whirlpool's earnings said, “Disappointment again? That’s only like 20 quarters in a row”.&nbsp;<stembedurl>https://stocktwits.com/Siksika/message/643306159</stembedurl>Another user on Stocktwits predicted that “the dividend is going to get cut or eliminated. They don’t have the cash this year from operations to fund their dividend.”<stembedurl>https://stocktwits.com/freddycan/message/643262444</stembedurl><h2 class="st-heading-2">Weak Forecast</h2>The company said on a full year basis in 2026, it expects net sales of $15.3 - $15.6 billion; approximately 5% growth vs 2025 like-for-like.&nbsp;It expects full-year ongoing earnings per diluted share of approximately $7.00, which was lower than the expectations of $7.21 per share by analysts.&nbsp;The company said it expects debt reduction of approximately $400 million as it continues to review all options to reduce debt that align with its capital allocation priorities and maximize shareholder value.&nbsp;“Price/mix to favorably impact our EBIT margin as we continue to deliver new product innovation and realize the momentum of our 2025 launches,” it said in a statement.&nbsp;<h2 class="st-heading-2">Earnings Miss</h2>The company reported fourth quarter adjusted earnings per share of $1.10, which fell well short of Wall Street consensus of $1.52 per share, according to data from fiscal.ai.Its revenue of $4.1 billion also came below analysts’ expectations of $4.27 billion. Its FY2025 sales of $15.5 billion, fell 6.5% compared to FY2024.&nbsp;“With a challenging 2025 behind us, our confidence for 2026 is based on our recent successful product launches, reduced promotional intensity and a gradual recovery of the housing market,” said CEO Marc Bitzer.&nbsp; &nbsp;

Close-up of logo for appliance company Whirlpool on a clothes dryer in a domestic room, August 21, 2019. 

WHR Slips 7% — Why Is Retail Expecting Whirlpool To Eliminate Dividend?

Whirlpool reported fourth quarter adjusted earnings per share of $1.10, which fell well short of Wall Street consensus of $1.52 per share, according to data from fiscal.ai.

Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?

5 High-Dividend ETFs to Earn Current Income 

Market looks overheated? Earn stable income with high-dividend ETFs ??? FGD, FDL, IDV, SPYD and DIVO ??? as volatility boosts the appeal of yield.

6 Dividend ETFs Under $50 to Buy Now

Market volatility sparks income hunt -- dividend ETFs like SCHD, CGDV, SPYD, IDV, FDL & DIVO under $50 offer steady yields and value.

<ul class="summary-bullets"><li>Battery electric vehicle sales, however, took a sharp hit, decreasing by 24.8% to 4,709 units, likely due to the expiration of the federal tax credit of $7,500 on the purchase of new EVs in the U.S. on September 30.&nbsp;</li><li>The F-series truck continued to be the company’s best-seller in October with 67,930 units sold, marking a growth of 0.7% year-over-year.&nbsp;</li><li>The company’s SUV sales, however, fell 4.7% last month to 65,968 units.&nbsp; &nbsp;</li></ul>Ford Motor Co. (F) on Monday said that it delivered 175,584 vehicles in the U.S. in October, marking a growth of 1.6% from the corresponding period last year, thanks to continued demand for its F-series trucks.The growth was primarily driven by a 3.4% growth in sales of the company’s internal combustion engine vehicles.<h2 class="st-heading-2">Electric Vehicle Sales Dive</h2>Battery electric vehicle sales, however, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://s205.q4cdn.com/882619693/files/doc_news/2025/Nov/03/Ford-U-S-October-2025-Sales-Release.pdf">took</a> a sharp hit, decreasing by 24.8% to 4,709 units, likely due to the expiration of the federal tax credit of $7,500 on the purchase of new EVs in the U.S. on September 30.While the company’s Mustang Mach-E sales dived 12.3% to 2,906 units, sales of its EV truck F-150 Lightning dropped 17.2% to 1,543 units. Sales of the company’s electric E-transit van, meanwhile, fell 76.1% to just 260 units.Last month, General Motors announced that it is canceling production of E-transit’s competitor, Brightdrop electric van, in Canada, citing slow development in the commercial electric van market.<h2 class="st-heading-2">F-Series Continues To Reign</h2>The F-series truck continued to be the company’s best-seller in October with 67,930 units sold, marking a growth of 0.7% year-over-year.The company’s SUV sales, however, fell 4.7% last month to 65,968 units, as sales of all of the company’s Lincoln brand SUVs fell, except the Navigator. The retirement of the Ford Edge SUV also weighed on the SUV sales numbers.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/F">F stock</a> is down by 1% at the time of writing. On Stocktwits, retail sentiment around F stock remained within the ‘bearish’ territory, while message volume decreased from ‘normal’ to ‘low’ levels.A Stocktwits user highlighted that November is typically a good month for autos.<stembedurl>https://stocktwits.com/ChumpMoney/message/634683037</stembedurl>F stock is up 31% this year and approximately 25% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-musks-1-trillion-pay-package-to-receive-overwhelming-approval/cL2NOFZR3zw">Gary Black Expects Musk’s $1T Pay Package To Receive ‘Overwhelming’ Approval But Warns Against Optimism On Tesla Robotaxi Expansion Plans</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Goldman Sachs reportedly upgraded the stock to ‘Buy’ from ‘Neutral’ and raised its price target to $13 from $12.

Ford Sales In US Rise 1.6% In October On Continued Truck Demand

The growth was primarily driven by a 3.4% growth in sales of the company’s internal combustion engine vehicles. 

The Zacks Analyst Blog Highlights Invesco QQQ Trust, Palantir, NVIDIA, Home Depot, S&P 500 Pure Value Invesco ETF and Morningstar Dividend Leaders ETF

Tech weakness pressures QQQ, Palantir and NVIDIA, while Home Depot, value ETFs and dividend funds attract investors amid sector rotation.

Time for a Sector Rotation Away from Tech? ETFs in Focus

Tech slump dragged QQQ lower as investors eye rotation into value ETFs like RPV, consumer staples ETFs like IYK, and dividend-focused ETFs like FDL.

Tap 4 Quality ETFs With Cheaper Valuation & Juicy Yields 

First Trust Exchange-Traded Fund III - First Trust Morningstar Dividend Leaders Index Fund

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

FDL
First Trust Exchange-Traded Fund III - First Trust Morningstar Dividend Leaders Index Fund

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FDL News

FDLFirst Trust Exchange-Traded Fund III - First Trust Morningstar Dividend Leaders Index Fund